Analyzing Trillium Therapeutics (TRIL) and Its Rivals
Trillium Therapeutics (NASDAQ: TRIL) is one of 95 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Trillium Therapeutics to similar businesses based on the strength of its risk, profitability, analyst recommendations, institutional ownership, valuation, dividends and earnings.
This is a summary of recent ratings and price targets for Trillium Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Trillium Therapeutics Competitors||122||460||1151||11||2.60|
Trillium Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 217.31%. As a group, “Biotechnology” companies have a potential upside of 48.50%. Given Trillium Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Trillium Therapeutics is more favorable than its competitors.
This table compares Trillium Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Trillium Therapeutics Competitors||-912.91%||-186.15%||-28.31%|
Institutional and Insider Ownership
48.0% of Trillium Therapeutics shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 19.6% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Trillium Therapeutics and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Trillium Therapeutics||N/A||-$28.62 million||-1.39|
|Trillium Therapeutics Competitors||$224.58 million||$58.11 million||-1.04|
Trillium Therapeutics’ competitors have higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Trillium Therapeutics has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Trillium Therapeutics’ competitors have a beta of 1.13, meaning that their average stock price is 13% more volatile than the S&P 500.
Trillium Therapeutics beats its competitors on 7 of the 12 factors compared.
About Trillium Therapeutics
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.